IL-33 is associated with alveolar dysfunction in patients with viral lower respiratory tract disease. Ian C Scott
Mucosal Immunol. 2024 Dec 9:S1933-0219(24)00124-7. doi: 10.1016/j.mucimm.2024.12.001. Online ahead of print. ABSTRACT Interleukin (IL)-33 is released following tissue damage, causing airway inflammation and remodelling via reduced IL-33 (IL-33red)/serum stimulation-2 (ST2) and oxidised IL-33 (IL-33ox)/receptor for advanced glycation end products (RAGE)/epidermal growth factor receptor (EGFR) pathways. This study aimed to identify associations of IL-33 with clinical … Read more